Pentoxifylline
NDC Package 67544-252-92

11-digit billing NDC: 67544025292 · Billing unit: EA · 270 EA per package

Package Information

This product is EXCLUDED from the official NDC directory because the listing data was inactivated by the FDA.

Pentoxifylline is extended-release tablets, USP are indicated for the treatment of patients with intermittent claudication on the basis of chronic occlusive arterial disease of the limbs. Marketed by Aphena Pharma Solutions - Tennessee, Llc, this product is identified by NDC 67544-252 and is authorized under FDA application ANDA075191.

Identification & Billing

NDC Package Code
67544-252-92
Package Description
270 TABLET, EXTENDED RELEASE in 1 BOTTLE, PLASTIC
Product Code
11-Digit Billing Format
67544025292
Billing Unit
EA - Billing unit of "each" is used when the product is dispensed in discreet units.
Units Per Package
270 EA
RxNorm Crosswalk
RxCUI: 312301 - pentoxifylline 400 MG Extended Release Oral Tablet

Clinical Specifications

Proprietary Name
Pentoxifylline
Dosage Form
-
Usage Information
Pentoxifylline extended-release tablets, USP are indicated for the treatment of patients with intermittent claudication on the basis of chronic occlusive arterial disease of the limbs. Pentoxifylline can improve function and symptoms but is not intended to replace more definitive therapy, such as surgical bypass, or removal of arterial obstructions when treating peripheral vascular disease.

Regulatory & Marketing

Labeler Name
Aphena Pharma Solutions - Tennessee, Llc
FDA Application #
ANDA075191
Marketing Category
ANDA - A product marketed under an approved Abbreviated New Drug Application.
Start Marketing Date
06-10-1999
Listing Expiration
12-31-2019
Exclude Flag
I
Sample Package
No

Hierarchy Structure

Code Lineage

The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

* Please review the full disclaimer at the bottom of this page.

Other Available Packages

The following commercial packages are registered under the same Product NDC (67544-252). Click a package code to view its specific billing and regulatory data.

90 TABLET, EXTENDED RELEASE in 1 BOTTLE, PLASTIC

* Please review the full disclaimer at the bottom of this page.

Frequently Asked Questions

What is the distribution configuration for this product package?

The code 67544-252-92 identifies a specific commercial package of 270 tablet, extended release in 1 bottle, plastic of Pentoxifylline, labeled by Aphena Pharma Solutions - Tennessee, Llc. This product is billed for "EA" each discreet unit and contains an estimated amount of 270 billable units per package. This is formulated for use and contains as the active substance.

Is this product currently listed with the FDA?

This product code is currently listed as inactive or excluded from the primary directory. It was introduced to the market by Aphena Pharma Solutions - Tennessee, Llc on June 10, 1999. The current certification is valid through December 31, 2019.

How is this Aphena Pharma Solutions - Tennessee, Llc product billed for insurance claims?

For medical billing and reimbursement, this package follows the 11-digit CMS format: 67544025292. Quantities are measured in per "each", products billed on a per each basis are usually products dispensed in discreet units.. There are 270 total billable units per package. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.

11-Digit Code Conversion

Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:

10-Digit Format (5-3-2)
67544-252-92
11-Digit CMS (5-4-2)
67544-0252-92

Note: The zero is added to the Product segment to maintain the 5-4-2 structure.